Jing Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Wei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Allen C Gao
Department of Urologic Surgery, University of California, Davis, Sacramento, CA, 95817, USA
1 shared publication- Boyang Jason Wu
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, USA
1 shared publication - Eva Corey
Department of Urology, University of Washington, Seattle, WA 98195, USA
1 shared publication - Jing Wang
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.
1 shared publication Jingjing Li
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA
1 shared publication- Tianjie Pu
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA
1 shared publication
Latest Publications
- Open Access
- 2 January 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (2) , 336-364
PlexinD1 is a driver and a therapeutic target in advanced prostate cancer
Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC). High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes. PlexinD1 critically maintains CRPC aggressive behaviors in vitro and in vivo, and confers stemness and cellular plasticity to promote multilineage differentiation including a neuroendocrine-like phenotype for ARSI resistance. Mechanistically, PlexinD1 is upregulated upon relief of AR-mediated transcriptional repression of PlexinD1 under ARSI treatment, and subsdquently transactivates ErbB3 and cMet via direct interaction, which triggers the ERK/AKT pathways to induce noncanonical Gli1-dictated Hedgehog signaling, facilitating the growth and plasticity of PCa cells. Blockade of PlexinD1 by the protein inhibitor D1SP restricted CRPC growth in multiple preclinical models. Collectively, these findings characterize PlexinD1’s contribution to PCa progression and offer a potential PlexinD1-targeted therapy for advanced PCa.
- 2 January 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (2) , 336-364
Open AccessPlexinD1 is a driver and a therapeutic target in advanced prostate cancer
Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC). High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes. PlexinD1 critically maintains CRPC aggressive behaviors in vitro and in vivo, and confers stemness and cellular plasticity to promote multilineage differentiation including a neuroendocrine-like phenotype for ARSI resistance. Mechanistically, PlexinD1 is upregulated upon relief of AR-mediated transcriptional repression of PlexinD1 under ARSI treatment, and subsdquently transactivates ErbB3 and cMet via direct interaction, which triggers the ERK/AKT pathways to induce noncanonical Gli1-dictated Hedgehog signaling, facilitating the growth and plasticity of PCa cells. Blockade of PlexinD1 by the protein inhibitor D1SP restricted CRPC growth in multiple preclinical models. Collectively, these findings characterize PlexinD1’s contribution to PCa progression and offer a potential PlexinD1-targeted therapy for advanced PCa.